Overall, the median time from biopsy to treatment was 35 days, but differed significantly between patients whose diagnosis ...

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their ...

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation ...

Standard of care for early ER-positive breast cancer includes 5-10 years of adjuvant endocrine therapy, which has been shown to reduce recurrence, decrease breast cancer mortality, and improve OS ...

NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult ...

Roche has been leading research into the HER2 pathway for over 30 years and is committed to improving the health, quality of ...